Axe Compute Inc. is focused on artificial intelligence (AI) compute accessible to all through its access to the Aethir network. By delivering Aethir-provided decentralized global infrastructure, the Company will endeavor to deliver instant access to bare-metal GPUs at scale to innovators and established businesses alike. Dedicated GPU clusters delivered in 48 hours across 200+ locations. It offers Zero Virtualization Overhead, Purpose-Built for AI Workloads, Flat Rate, Zero Egress Fees, and Enterprise-Grade Support and SLAs. It provides 100% bare-metal access.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	40.94M 35.26M 32.45M 30.49M 57.27M 3.87B 57.93M 383M 149M 1.9B 154M 150M 6.57B	P/E Ratio 2024	-0.35x	P/E Ratio 2025	-0.53x
Enterprise Value	31.81M 27.4M 25.22M 23.69M 44.51M 3.01B 45.02M 297M 116M 1.47B 119M 117M 5.1B	EV / Sales 2024	4.23x	EV / Sales 2025	121x
Free-Float	87.13%	Yield 2024 *	-	Yield 2025	-

06-16	Axe Compute Inc. Secures $25.9 Million in Contracts for Long-Term Deployments of Blackwell and Grace Blackwell Compute	CI
06-10	Axe Compute Files $1 Billion Mixed Shelf	MT
05-27	Axe Compute Inc. Receives $43 Million Payment for Landmark Contract	CI
05-18	Axe Compute Inc., Q1 2026 Earnings Call, May 18, 2026
04-22	Top Midday Gainers	MT
04-22	Axe Compute Receives $260 Million Contract to Provide Nvidia B300 Chips; Shares Jump Pre-Bell	MT
04-22	Axe Compute Inc Secures $260 Million Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment	CI
04-20	Axe Compute Inc Announces Strategic Compute Reserve Dashboard Launch	CI
04-17	Axe Compute Inc - Josh Blacher to resign as CFO effective May 18, 2026 - SEC filing	RE
04-17	Axe Compute Inc. Announces Change of Chief Financial Officer	CI
04-06	Axe Compute Names Kyle Okamoto President, Effective April 1, 2026	CI
04-02	Axe Compute appoints Kyle Okamoto as president effective April 1, 2026 - SEC filing	RE
04-01	Axe Compute Inc., 2025 Earnings Call, Apr 01, 2026

15/11/24	HC Wainwright Downgrades Predictive Oncology to Neutral From Buy	MT
30/06/21	PREDICTIVE ONCOLOGY : HC Wainwright Starts Predictive Oncology at Buy With $5 Price Target	MT

06-16	Axe Compute Secures $25.9 Million in Contracts for Long-Term Deployments of Blackwell and Grace Blackwell Compute	AQ
05-27	Axe Compute Receives $43M Payment for Landmark Contract	AQ
05-16	Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05-11	Axe Compute to Host Q1 2026 Financial Results Conference Call	AQ
05-04	Axe Compute Inc. (NASDAQ: AGPU) CEO Chris Miglino to Appear on Schwab Network May 4 and Cheddar May 6	AQ

16/03/21	MÄRKTE USA/Wall Street mit Fed-Sitzung in Lauerstellung
16/03/21	New Fortress Energy : MÄRKTE USA/Wall Street mit Fed-Sitzung uneinheitlich
16/03/21	New Fortress Energy : MÄRKTE USA/S&P-500 mit Rekordhoch trotz enttäuschender US-Daten
16/03/21	New Fortress Energy : MÄRKTE USA/Wenig verändert - US-Daten liefern gemischtes Bild
16/03/21	New Fortress Energy : MARKT USA/Wenig verändert - US-Daten könnten Impulse liefern

Precision Therapeutics Inc Stock Nasdaq

Stocks

US74033P1003

Biotechnology & Medical Research

Valuation: Precision Therapeutics Inc

Latest news : Precision Therapeutics Inc

Last Transcript: Precision Therapeutics Inc

Analysts' recommendations: Precision Therapeutics Inc

Press Releases: Precision Therapeutics Inc

News in other languages: Precision Therapeutics Inc

Quotes and Performance

Managers and Directors: Precision Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Christopher Miglino CEO	Chief Executive Officer	57	09/02/2026
Jeremy Yaukey-Witter DFI	Director of Finance/CFO	-	16/04/2026
Kyle Okamoto PSD	President	-	01/04/2026

Director	Title	Age	Since
Daniel Handley BRD	Director/Board Member	66	19/02/2020
Charles L. Nuzum CHM	Chairman	78	09/02/2026
Gregory St. Clair BRD	Director/Board Member	60	09/07/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PRECISION THERAPEUTICS INC	-7.56%	-8.33%	-	-	40.49M
LONZA GROUP AG	-0.12%	+1.04%	-13.08%	-12.43%	43.58B
REVOLUTION MEDICINES, INC.	-2.17%	+5.45%	+285.76%	+522.83%	34.03B
IQVIA HOLDINGS INC.	+0.44%	-2.46%	+14.20%	-17.35%	29.77B
BEONE MEDICINES AG	-1.60%	-2.54%	-2.12%	+31.28%	29.82B
CELLTRION, INC.	-0.29%	+9.47%	+13.95%	+21.93%	25.42B
ASCENDIS PHARMA A/S	+3.54%	+12.34%	-	-	13.87B
MEDPACE HOLDINGS, INC.	-1.26%	+0.81%	+54.77%	+109.24%	13.35B
EUROFINS SCIENTIFIC SE	-1.04%	-3.33%	+3.98%	+3.91%	12.85B
IONIS PHARMACEUTICALS, INC.	-1.18%	-0.61%	+105.37%	+75.32%	12.22B
Average	-1.12%	+2.03%	+57.85%	+91.84%	23.88B
Weighted average by Cap.	-0.54%	+2.02%	+59.38%	+102.72%

	2024	2025
Net sales	1.62M 1.4M 1.29M 1.21M 2.27M 154M 2.3M 15.18M 5.92M 75.19M 6.09M 5.96M 260M	125K 108K 99.32K 93.31K 175K 11.85M 177K 1.17M 457K 5.8M 470K 460K 20.1M
Net income	-12.66M -10.91M -10.04M -9.43M -17.72M -1.2B -17.92M -118M -46.2M -586M -47.52M -46.52M -2.03B	-233M -201M -185M -174M -326M -22.05B -330M -2.18B -850M -10.79B -875M -856M -37.39B
Net Debt	1.4M 1.2M 1.11M 1.04M 1.95M 132M 1.98M 13.06M 5.09M 64.66M 5.24M 5.13M 224M	-9.12M -7.86M -7.23M -6.8M -12.77M -863M -12.91M -85.32M -33.28M -423M -34.24M -33.51M -1.46B